hydroxyurea has been researched along with Fatigue in 7 studies
Fatigue: The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study aims to determine the maximum tolerated dose (MTD) of clofarabine combined with the EORTC-GIMEMA 3 + 10 induction regimen (idarubicin + cytosine arabinoside) in adults with untreated acute myelogenous leukemia or high-risk myelodysplastic syndrome." | 9.19 | Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): p ( Amadori, S; de Witte, T; Halkes, CJ; Karrasch, M; Marie, JP; Meert, L; Meloni, G; Muus, P; Rapion, J; Suciu, S; Vignetti, M; Willemze, R, 2014) |
| "This study aims to determine the maximum tolerated dose (MTD) of clofarabine combined with the EORTC-GIMEMA 3 + 10 induction regimen (idarubicin + cytosine arabinoside) in adults with untreated acute myelogenous leukemia or high-risk myelodysplastic syndrome." | 5.19 | Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): p ( Amadori, S; de Witte, T; Halkes, CJ; Karrasch, M; Marie, JP; Meert, L; Meloni, G; Muus, P; Rapion, J; Suciu, S; Vignetti, M; Willemze, R, 2014) |
| " Adverse events were primarily grades 1/2 with no unexpected safety signals." | 2.84 | The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF). ( Byrne, J; Garg, M; Habr, D; Hasan, Y; Hunter, D; Jones, MM; Koschmieder, S; Lyons, R; Martino, B; Mesa, R; Passamonti, F; Rinaldi, C; Vannucchi, AM; Verstovsek, S; Yacoub, A; Zachee, P; Zhen, H, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bertolini, F | 1 |
| Cassisa, A | 1 |
| Miggiano, MC | 1 |
| Gasparin, P | 1 |
| Willemze, R | 1 |
| Suciu, S | 1 |
| Muus, P | 1 |
| Halkes, CJ | 1 |
| Meloni, G | 1 |
| Meert, L | 1 |
| Karrasch, M | 1 |
| Rapion, J | 1 |
| Vignetti, M | 1 |
| Amadori, S | 1 |
| de Witte, T | 1 |
| Marie, JP | 1 |
| Stein, BL | 1 |
| Moliterno, AR | 1 |
| Tiu, RV | 1 |
| Geyer, H | 1 |
| Scherber, R | 1 |
| Kosiorek, H | 1 |
| Dueck, AC | 1 |
| Kiladjian, JJ | 1 |
| Xiao, Z | 1 |
| Slot, S | 1 |
| Zweegman, S | 1 |
| Sackmann, F | 1 |
| Fuentes, AK | 1 |
| Hernández-Maraver, D | 1 |
| Döhner, K | 1 |
| Harrison, CN | 1 |
| Radia, D | 1 |
| Muxi, P | 1 |
| Besses, C | 1 |
| Cervantes, F | 1 |
| Johansson, PL | 1 |
| Andreasson, B | 1 |
| Rambaldi, A | 1 |
| Barbui, T | 1 |
| Bonatz, K | 1 |
| Reiter, A | 1 |
| Boyer, F | 1 |
| Etienne, G | 1 |
| Ianotto, JC | 1 |
| Ranta, D | 1 |
| Roy, L | 1 |
| Cahn, JY | 1 |
| Maldonado, N | 1 |
| Barosi, G | 1 |
| Ferrari, ML | 1 |
| Gale, RP | 1 |
| Birgegard, G | 1 |
| Xu, Z | 1 |
| Zhang, Y | 1 |
| Sun, X | 1 |
| Xu, J | 1 |
| Zhang, P | 1 |
| te Boekhorst, PA | 1 |
| Commandeur, S | 1 |
| Schouten, H | 1 |
| Pahl, HL | 1 |
| Griesshammer, M | 1 |
| Stegelmann, F | 1 |
| Lehmann, T | 1 |
| Senyak, Z | 1 |
| Vannucchi, AM | 2 |
| Passamonti, F | 2 |
| Samuelsson, J | 1 |
| Mesa, RA | 1 |
| Mesa, R | 1 |
| Yacoub, A | 1 |
| Zachee, P | 1 |
| Garg, M | 1 |
| Lyons, R | 1 |
| Koschmieder, S | 1 |
| Rinaldi, C | 1 |
| Byrne, J | 1 |
| Hasan, Y | 1 |
| Verstovsek, S | 1 |
| Hunter, D | 1 |
| Jones, MM | 1 |
| Zhen, H | 1 |
| Habr, D | 1 |
| Martino, B | 1 |
| Vogler, S | 1 |
| Burkhard, R | 1 |
| Cortes, J | 1 |
| Kantarjian, H | 1 |
| O'Brien, S | 1 |
| Robertson, LE | 1 |
| Pierce, S | 1 |
| Talpaz, M | 1 |
1 review available for hydroxyurea and Fatigue
| Article | Year |
|---|---|
Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options.
Topics: Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cost of Illness; Disease Progression | 2014 |
3 trials available for hydroxyurea and Fatigue
3 other studies available for hydroxyurea and Fatigue
| Article | Year |
|---|---|
Skin nodules in onset of acute myeloid leukemia, a myelomonocytic variant case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cytarabine; Daunorubicin; Delayed Diagnosis; | 2017 |
Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Fatigue; Female; Fever; Humans; Hydroxyurea; | 2016 |
[A 69-year-old man with deep fatigue, weight loss and eosinophilia].
Topics: Administration, Oral; Aged; Anti-Inflammatory Agents; Diagnosis, Differential; Fatigue; Follow-Up St | 2005 |